An Economic Analysis of Empagliflozin versus Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) in the United Kingdom (UK)

Reifsnider O1, Tafazzoli A1, Bellanca L1, Litkiewicz M1, Stargardt M1, Linden S4

1 Evidera, Bethesda, MD, USA; 2 Boehringer Ingelheim Ltd., Berkshire, UK; 3 Evidera, London, UK; 4 Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany

INTRODUCTION

Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) in the United Kingdom (UK)

OBJECTIVE

METHODS

Initial population was the same as patients with HFrEF who were not treated with ARNi at baseline in the EMPEROR-Reduced trial (constituting approximately 80.5% of the trial population) but including patient-level data from the EMPEROR-Reduced trial subpopulation without ARNi use at baseline (Table 1).

RESULTS

CONCLUSIONS

REFERENCES

LIMITATIONS

An Economic Analysis of Empagliflozin versus Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) in the United Kingdom (UK)